Duncker Streett & Co. Inc. Cuts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Duncker Streett & Co. Inc. trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,406 shares of the medical research company’s stock after selling 57 shares during the period. Thermo Fisher Scientific comprises 3.0% of Duncker Streett & Co. Inc.’s holdings, making the stock its 4th biggest holding. Duncker Streett & Co. Inc.’s holdings in Thermo Fisher Scientific were worth $14,016,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Tyche Wealth Partners LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $1,283,000. Arbor Trust Wealth Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $209,000. HealthInvest Partners AB purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $6,059,000. Avior Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 3.3% in the 4th quarter. Avior Wealth Management LLC now owns 3,938 shares of the medical research company’s stock worth $2,091,000 after purchasing an additional 126 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Thermo Fisher Scientific by 28.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 399,232 shares of the medical research company’s stock worth $211,908,000 after purchasing an additional 89,190 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,277 shares of company stock valued at $28,513,384. Corporate insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Raymond James upped their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. The Goldman Sachs Group increased their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Finally, Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price for the company. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $601.56.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $3.32 during trading on Wednesday, hitting $554.55. 1,010,299 shares of the company’s stock were exchanged, compared to its average volume of 1,115,688. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. The business has a 50-day simple moving average of $571.67 and a 200-day simple moving average of $526.87. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The stock has a market capitalization of $211.68 billion, a price-to-earnings ratio of 35.90, a PEG ratio of 2.34 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same quarter last year, the company posted $5.40 earnings per share. The firm’s revenue was down 4.9% compared to the same quarter last year. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.